F2G’s attempt to end a two-decade drought in novel therapies for invasive fungal infections has hit a hurdle after the FDA said it was unable to approve its olorofim candi
SNIPR Biome has said its CRISPR therapeutic targeting a problem bacterial pathogen has shown proof-of-concept in a phase 1 trial, raising hopes of a new way to treat resis
The FDA has given a green light to Innoviva’s antibiotic combination Xacduro, which becomes the first drug specifically approved for pneumonia caused by hard-to-treat bact
Pollution by the pharmaceutical, healthcare, and agricultural sectors is driving the development of 'superbug' strains of bacteria that have become resistant to every know
A pharma company’s core mission is to improve patient outcomes. This hinges on effectively influencing HCP clinical behaviour and driving disease education.
